Literature DB >> 11481297

Comparative evaluation of oral levofloxacin and parenteral nafcillin in the treatment of experimental methicillin-susceptible Staphylococcus aureus osteomyelitis in rabbits.

M E Shirtliff1, J H Calhoun, J T Mader.   

Abstract

Methicillin-susceptible Staphylococcus aureus (MSSA) is the most common pathogen recovered from osteomyelitis patients. The current standard therapeutic method for acute phase osteomyelitis is parenteral antibiotic therapy. However, parenteral administration has negative aspects, such as secondary infection, patient inconvenience and high cost. The use of single oral antibiotic therapy may alleviate these problems. Therefore, the purpose of this study was to compare the effectiveness of standard once per day dosing of oral levofloxacin with a standard parenteral antibiotic regimen (nafcillin four times daily) for the treatment of experimental MSSA osteomyelitis in rabbits. Nearly all tibias from untreated infected controls (n = 27) revealed positive cultures (93%) for S. aureus, while the levofloxacin-treated group (n = 20) demonstrated significantly lower percentages of S. aureus infection (50%). The infected tibias of the nafcillin-treated group (n = 20) demonstrated significantly lower percentages (10%) of infected tibias than either the controls or the levofloxacin-treated groups (P < 0.05). The inferior efficacy of levofloxacin may have been due to the pharmacokinetic profile of this fluoroquinolone. The serum kinetics demonstrated that following single dose administration, levofloxacin was almost undetectable after 12 h. Studies in which levofloxacin is dosed every 12 h or given at increased doses in order to obtain bactericidal concentrations throughout the treatment regimen are needed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11481297     DOI: 10.1093/jac/48.2.253

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention.

Authors:  O C El Helou; E F Berbari; B D Lahr; J E Eckel-Passow; R R Razonable; I G Sia; A Virk; R C Walker; J M Steckelberg; W R Wilson; A D Hanssen; D R Osmon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-27       Impact factor: 3.267

2.  Global sensitivity analysis used to interpret biological experimental results.

Authors:  Angela M Jarrett; Yaning Liu; N G Cogan; M Yousuff Hussaini
Journal:  J Math Biol       Date:  2014-07-25       Impact factor: 2.259

3.  Development of a Novel and Rapid Antibody-Based Diagnostic for Chronic Staphylococcus aureus Infections Based on Biofilm Antigens.

Authors:  Janette M Harro; Mark E Shirtliff; William Arnold; Jennifer M Kofonow; Chad Dammling; Yvonne Achermann; Kristen Brao; Javad Parvizi; Jeff G Leid
Journal:  J Clin Microbiol       Date:  2020-04-23       Impact factor: 5.948

4.  Osteomyelitis of the long bones.

Authors:  Jason H Calhoun; M M Manring; Mark Shirtliff
Journal:  Semin Plast Surg       Date:  2009-05       Impact factor: 2.314

5.  Modelling the interaction between the host immune response, bacterial dynamics and inflammatory damage in comparison with immunomodulation and vaccination experiments.

Authors:  Angela M Jarrett; N G Cogan; M E Shirtliff
Journal:  Math Med Biol       Date:  2014-05-08       Impact factor: 1.854

6.  Diagnosis and treatment of implant-associated septic arthritis and osteomyelitis.

Authors:  Andrej Trampuz; Werner Zimmerli
Journal:  Curr Infect Dis Rep       Date:  2008-09       Impact factor: 3.725

7.  A different perspective for radiological evaluation of experimental osteomyelitis.

Authors:  Cem Nuri Aktekin; Akif Muhtar Ozturk; Abdullah Yalcin Tabak; Murat Altay; Feza Korkusuz
Journal:  Skeletal Radiol       Date:  2007-07-12       Impact factor: 2.199

Review 8.  Antimicrobial agents in orthopaedic surgery: Prophylaxis and treatment.

Authors:  Andrej Trampuz; Werner Zimmerli
Journal:  Drugs       Date:  2006       Impact factor: 11.431

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.